Retail drug prices up 25 percent, government report finds

Share this article:
Retail drug prices increased 25 percent nationwide from 2000 to 2004, according to a report from the Government Accountability Office (GAO) yesterday. 
The report found that the price of a 30-day supply of 96 drugs commonly used by older Americans rose 24.5 percent from January 2000 through December 2004.
Twenty of the medications accounted for almost two-thirds of the increase, the report said.
"The drug with the largest effect on the price index was Lipitor 10 mg, which accounted for 6.6 percent of the total increase," the report read.
Lipitor is the world's best-selling prescription drug with approximately $12 billion in global sales.
The analysis took into account the usual price paid by uninsured patients at retail pharmacies, the average price paid to drug makers by wholesalers and the list prices manufacturers suggest for sales to pharmacies, the report said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...